ArticleTherapeutics and clinical risk management2007
Infliximab in the treatment of Crohn's disease.
Article in Therapeutics and clinical risk management, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Infliximab for maintenance of medically-induced remission in Crohn's disease.The Cochrane database of systematic reviews · 2024Pooled it
- Trial
- Development and validation of a LASSO-logistic regression model for predicting subtherapeutic infliximab trough concentrations in patients with Crohn's disease.International journal of clinical pharmacy · 2026Article
- Baricitinib and Infliximab Mitigate the Endothelial-to-Mesenchymal Transition (EndMT) Induced by Cytokines in HUVECs.International journal of molecular sciences · 2025Article
- Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function.Diabetologia · 2025Article
- Identification of Potential Functional Modules and Diagnostic Genes for Crohn's Disease Based on Weighted Gene Co-expression Network Analysis and LASSO Algorithm.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Predictive biomarkers for anti-TNF alpha therapy in IBD patients.Journal of translational medicine · 2024Review
- Gluteal and Presacral Abscess Due to Crohn's Disease with Multiple Fistulas.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Article
- Surgical Management of Inflammatory Bowel Disease.Rhode Island medical journal (2013) · 2022Article
- Attenuation of Excess TNF-α Release in Crohn's Disease by Silencing of iRHOMs 1/2 and the Restoration of TGF-β Mediated Immunosuppression Through Modulation of TACE Trafficking.Frontiers in immunology · 2022Article
- The Impact of Ageing on the CNS Immune Response in Alzheimer's Disease.Frontiers in immunology · 2021Review
- Characterisation of CD4+ T-cell subtypes using single cell RNA sequencing and the impact of cell number and sequencing depth.Scientific reports · 2020Article
- Clinical implications of nicotine as an antimicrobial agent and immune modulator.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Review
- Medical Management of Crohn's Disease.Cureus · 2020Review
- Transcriptome-Guided Drug Repositioning.Pharmaceutics · 2019Article
- Resolution of Metastatic Colon Cancer upon Withdrawal of Anti-TNF Therapy for Crohn's Disease.Journal of gastrointestinal cancer · 2019Article
- Anti-TNF Therapy in Crohn's Disease.International journal of molecular sciences · 2018Review
- Review of local injection of anti-TNF for perianal fistulising Crohn's disease.International journal of colorectal disease · 2017Review
- Ileal pouch-anal anastomosis 20 years later: is it still a good surgical option for patients with ulcerative colitis?International journal of colorectal disease · 2016Article
- Intra-abdominal fistulas in surgically treated Crohn's disease patients.World journal of surgery · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent introduction of infliximab, a chimeric monoclonal antibody against tumor necrosis factor-alpha, has greatly modified the treatment of Crohn's disease (CD). Data from the literature show encouraging results after intravenous infusion both for closure of intestinal or perianal fistulas and for induction and maintenance of remission in patients with moderate to severe intestinal disease unresponsive to other treatments. However, some contraindications such as fibrostenosing CD and sepsis have been identified. In addition, the data on long-term outcomes and safety is still limited. Our initial experience showed that in selected cases local injection of infliximab is effective in the treatment of complex perianal disease offering the possibility of using such treatment even in small bowel obstructing disease with minimal systemic effects. This paper analyzes the state of the use of both intravenous and local injection of infliximab in patients with CD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.